| pubmed-article:18418404 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0242596 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0600554 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:18418404 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:18418404 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:18418404 | pubmed:dateCreated | 2008-7-16 | lld:pubmed |
| pubmed-article:18418404 | pubmed:abstractText | The purpose of this study was to prospectively analyze minimal residual disease(MRD) kinetics after reduced-intensity allogeneic stem cell transplantation (allo-SCT) in high-risk chronic lymphocytic leukemia (CLL). Subjects were the first 30 consecutive patients from a prospective clinical trial, and seven pilot patients treated identically. Using real-time quantitative-PCR (RQ-PCR) and/or flow-based MRD monitoring (sensitivity >or=10(-4)), five distinct patterns of MRD kinetics could be identified: patients who promptly achieved durable MRD negativity without direct evidence of graft-versus-leukemia (GVL) effects (Group 1) (n=4; no clinical relapse); patients with complete and sustained MRD response after GVL induced by immunosuppression tapering (Group 2) or donor lymphocyte infusions (Group 3) (n=18; one relapse); patients without MRD response due to lack of GVL (Group 4) (n=2; two relapses); patients with incomplete and transient MRD response to GVL (Group 5) (n=4; three relapses). In summary, this study provides a comprehensive map of possible MRD courses and their prognostic implications after T-replete allo-SCT in high-risk CLL, indicating that effective GVL activity is induced virtually in all patients who develop chronic GVHD. However, in a significant proportion of cases, this does not translate into sustained disease control due to development of secondary GVL resistance. | lld:pubmed |
| pubmed-article:18418404 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18418404 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18418404 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18418404 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18418404 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18418404 | pubmed:issn | 1476-5551 | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:SchubertJJ | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:CohenSS | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:DöhnerHH | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:BunjesDD | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:SchmitzNN | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:HallekMM | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:KnebaMM | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:DregerPP | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:StilgenbauerS... | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:BöttcherSS | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:HumpeAA | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:RitgenMM | lld:pubmed |
| pubmed-article:18418404 | pubmed:author | pubmed-author:German CLL... | lld:pubmed |
| pubmed-article:18418404 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18418404 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:18418404 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18418404 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18418404 | pubmed:pagination | 1377-86 | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:meshHeading | pubmed-meshheading:18418404... | lld:pubmed |
| pubmed-article:18418404 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18418404 | pubmed:articleTitle | Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. | lld:pubmed |
| pubmed-article:18418404 | pubmed:affiliation | Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany. | lld:pubmed |
| pubmed-article:18418404 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18418404 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18418404 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:18418404 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18418404 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18418404 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18418404 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18418404 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18418404 | lld:pubmed |
